Inflammation is responsible for systemic bone loss in patients with seropositive rheumatoid arthritis treated with rituximab

CONCLUSIONS: Systemic inflammation, reflected by increased disease activity, may be responsible for the increase in RANKL levels, which causes systemic bone loss in rituximab-treated patients with RA. Although rituximab affects inflammation, it does not seem to alter systemic bone metabolism in RA.PMID:37867140 | DOI:10.3904/kjim.2023.080

Source: The Korean Journal of Internal Medicine - October 22, 2023 Category: Internal Medicine Authors: Mie Jin Lim Kyong-Hee Jung Seong-Ryul Kwon Won Park Source Type: research